c-Abl Demonstrates Potential as a Key Therapeutic Target in Parkinson ' s Disease and Related Disorders

BOSTON and ATLANTA, Jan. 25, 2023. Inhibikase Therapeutics, Inc. ( " Inhibikase " or " Company " ), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson ' s disease, Parkinson ' s-related...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials